1. Introduction: The Cognitive Peptide Landscape

Three peptides sit at the center of every serious cognitive enhancement conversation: Semax, Selank, and Dihexa. Each targets a different piece of brain chemistry, and none are interchangeable. Choosing between them depends on what cognitive outcome you're studying, what level of risk is acceptable, and whether you prioritize decades of clinical safety data or raw mechanistic potency.

The global nootropic peptides market has grown significantly in 2025–2026, driven by increasing research into neurodegenerative disease models, cognitive optimization, and stress resilience. According to industry analysis, the cognitive enhancement peptide segment is one of the fastest-growing categories in research chemical procurement, with Semax and Dihexa among the most frequently requested compounds by neuroscience laboratories worldwide.

This guide provides a comprehensive, evidence-based comparison of all three peptides — from molecular structure and mechanism to dosing protocols and sourcing standards — designed to help researchers, formulators, and procurement teams make informed decisions.

2. Molecular Mechanisms: Three Different Brain Targets

Although all three compounds are classified as cognitive peptides, their mechanisms of action are fundamentally distinct. This is why they are studied for different applications and cannot be treated as interchangeable.

The critical distinction: Semax and Selank modulate existing neurotransmitter systems (dopamine, serotonin, GABA), producing effects that are immediate and reversible. Dihexa activates growth factor signaling that physically constructs new synaptic connections — a fundamentally different and more powerful mechanism with correspondingly less understood long-term implications.

3. Semax: The Focus & BDNF Amplifier

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It was developed in the 1980s by the Russian Academy of Medical Sciences from a fragment of adrenocorticotropic hormone (ACTH), specifically the ACTH(4-7) sequence, but stripped of ACTH's hormonal (corticosteroid-releasing) activity. The C-terminal Pro-Gly-Pro tripeptide was added for enzymatic stability.

Product Name	Semax (ACTH 4-7 analog)
CAS Number	80714-61-0
Molecular Formula	C₃₇H₅₁N₉O₁₀S
Molecular Weight	813.92 g/mol
Sequence	Met-Glu-His-Phe-Pro-Gly-Pro
Mechanism	BDNF & NGF upregulation via CREB pathway; dopaminergic modulation
Primary Research Use	Cognitive enhancement, neuroprotection, stroke recovery models
Administration Route	Intranasal (primary); subcutaneous (research)
Regulatory Status	Approved pharmaceutical in Russia & Ukraine
Purity Standard	≥98% (HPLC verified)

How Semax Works

Semax's primary mechanism is BDNF (brain-derived neurotrophic factor) amplification. BDNF is the brain's most important growth protein — it supports neuron survival, promotes synaptic plasticity, and drives neurogenesis. In animal models, a single intranasal dose of Semax at 50 μg/kg produces measurable neurochemical changes:

• 1.4-fold increase in BDNF protein levels in the hippocampus
• 1.6-fold increase in TrkB tyrosine phosphorylation (the receptor BDNF binds to)
• 3-fold increase in exon III BDNF mRNA expression
• 2-fold increase in TrkB mRNA levels
• 500% increase in NGF (nerve growth factor) mRNA

Semax also modulates dopamine signaling, which contributes to its effects on focus, motivation, and executive function. Additionally, it activates neuroprotective pathways that reduce oxidative stress damage and protect neurons from ischemic injury.

Clinical Evidence

Semax is approved in Russia and Ukraine for ischemic stroke, encephalopathy, optic nerve atrophy, and cognitive disorders. It was added to Russia's List of Vital and Essential Drugs in 2011 — not a fringe compound, but an established pharmaceutical in those jurisdictions. A clinical trial in 110 post-stroke patients demonstrated that Semax treatment (6,000 mcg/day intranasally) produced higher BDNF plasma levels, faster functional recovery, and improved motor performance compared to controls.

4. Selank: The Anxiolytic With Cognitive Upside

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), developed in parallel with Semax at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from tuftsin, a naturally occurring immunomodulatory peptide (Thr-Lys-Pro-Arg) that is a fragment of the Fc region of immunoglobulin G. The Pro-Gly-Pro tripeptide was appended to tuftsin's C-terminus to dramatically increase its enzymatic stability — natural tuftsin has a plasma half-life measured in seconds, while Selank is stable long enough for clinical utility.

Product Name	Selank (Tuftsin analog)
CAS Number	129954-34-3
Molecular Formula	C₃₃H₅₇N₁₁O₉
Molecular Weight	751.89 g/mol
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Mechanism	GABA-A allosteric modulation; enkephalin stabilization; serotonin regulation
Primary Research Use	Anxiety reduction, stress resilience, immune modulation
Administration Route	Intranasal (primary); subcutaneous (research)
Regulatory Status	Approved in Russia for generalized anxiety disorder (2009)
Purity Standard	≥98% (HPLC verified)

How Selank Works

Selank's most clinically significant mechanism is its allosteric modulation of GABA-A receptors. Unlike benzodiazepines, which bind directly to the benzodiazepine site and produce potent but sedating anxiolysis (with risks of dependence and withdrawal), Selank modulates GABAergic neurotransmission indirectly. It alters the expression of genes encoding GABA-A receptor subunits and GABA transporters without the full receptor occupancy that produces sedation, muscle relaxation, and dependence.

Additional mechanisms include:

• Enkephalin stabilization: Selank inhibits enzymes that degrade enkephalins (the brain's natural stress-buffering molecules), extending their activity
• Serotonin and dopamine regulation: Helps balance mood-related neurotransmitters
• Immune modulation: Retains tuftsin's immunomodulatory properties — documented antiviral activity against influenza A (H3N2) via interferon-alpha induction
• Mild BDNF effects: Some evidence of BDNF expression support, though weaker than Semax

5. Dihexa: The Synaptogenesis Powerhouse

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an angiotensin IV analog developed by Joe Harding's laboratory at Washington State University. Unlike Semax and Selank, which have decades of Russian clinical use, Dihexa is a newer compound with compelling preclinical data but no published human clinical trials. It is the most experimentally potent of the three — and the least characterized in humans.

Product Name	Dihexa (Angiotensin IV analog)
CAS Number	1401708-83-5
Molecular Formula	C₂₇H₄₄N₄O₅
Molecular Weight	504.66 g/mol
Mechanism	HGF/c-Met potentiation; synaptogenesis induction
Primary Research Use	Synaptic plasticity, memory consolidation, neural repair models
Administration Route	Oral (bioavailable); subcutaneous; transdermal (DMSO carrier)
Regulatory Status	Research compound — not approved in any jurisdiction
Purity Standard	≥98% (HPLC verified)

How Dihexa Works

Dihexa's primary mechanism is potentiation of hepatocyte growth factor (HGF) signaling through the c-Met receptor. HGF/c-Met signaling is a critical pathway for synaptogenesis — the formation of new synaptic connections between neurons. In hippocampal slice models, Dihexa was reported to be approximately 10 million times more potent than BDNF at promoting spinogenesis and synaptogenesis.

This is a fundamentally different mechanism from Semax (which increases BDNF production) or Selank (which modulates GABA). Dihexa doesn't just enhance existing signaling — it physically drives the construction of new neural connections. This makes it extraordinarily interesting for research into cognitive recovery, but also raises questions about long-term safety that the other two peptides don't face.

Preclinical Evidence

In animal studies conducted at Washington State University, Dihexa demonstrated:

• Significant cognitive improvement in aged rodent models
• Reversal of spatial learning deficits in scopolamine-induced memory impairment models
• Enhanced dendritic spine formation in hippocampal neurons
• Oral bioavailability — unusual among peptide tool compounds, enabling non-invasive administration

6. Head-to-Head Comparison: Key Differences

The following table summarizes the critical differences across all major dimensions:

Feature	Semax	Selank	Dihexa
Parent Molecule	ACTH(4-7) fragment	Tuftsin (IgG Fc fragment)	Angiotensin IV analog
Primary Target	BDNF / TrkB / Dopamine	GABA-A / Serotonin / Immune	HGF / c-Met
Main Cognitive Benefit	Focus, memory, learning speed	Anxiety reduction, calm clarity	Synaptogenesis, neural repair
Effect Onset	Minutes to hours (acute)	5–15 minutes (acute)	Days to weeks (structural)
Effect Duration	12–24 hours per dose	4–8 hours per dose	Weeks to months (persistent)
Administration	Intranasal spray	Intranasal spray	Oral / subcutaneous / transdermal
Oral Bioavailability	Poor (intranasal preferred)	Poor (intranasal preferred)	Good (orally active)
Human Clinical Trials	Yes (Russia/Ukraine)	Yes (Russia)	None
Regulatory Approval	Approved in Russia (Vital Drugs List)	Approved in Russia (2009)	None anywhere
Risk Level	Low (decades of clinical use)	Low (decades of clinical use)	Higher (experimental)
Addiction Potential	None documented	None documented (non-sedating)	Unknown (no human data)
Withdrawal Risk	None documented	None documented	Unknown
Immunomodulatory	No	Yes (tuftsin-derived)	No
CAS Number	80714-61-0	129954-34-3	1401708-83-5

7. Dosing & Administration Reference Guide

Parameter	Semax	Selank	Dihexa
Standard Research Dose	200–600 mcg intranasal, 1–2× daily	200–400 mcg intranasal, 2–3× daily	5–20 mg oral, weekly or daily
Onset Time	10–20 minutes	5–15 minutes	1–3 days (subjective); weeks (structural)
Cycle Length	10–30 days, then 2–4 week break	14 days, then 1 month break	2–4 weeks on, 2–4+ weeks off
Russian Clinical Dose (Stroke)	Up to 6,000 mcg/day (1% solution)	N/A (anxiety indication)	N/A
Storage	Refrigerated (2–8°C); degrades at room temp	Refrigerated (2–8°C)	−20°C lyophilized; protect from light
N-Acetyl Variants	NA-Semax (~50–75% lower dose)	NASA-Selank (proposed better BBB penetration)	N/A

For intranasal administration, the standard reconstitution target for research-grade Semax and Selank is a 0.3% solution (~30 mg per 10 mL), delivering approximately 300 mcg per metered actuation. Note that liquid Semax degrades relatively quickly at room temperature — refrigeration between uses is essential for research integrity.

8. Stacking Strategies: How They Work Together

Because Semax, Selank, and Dihexa target entirely different brain pathways, they can be combined in research settings without pharmacological antagonism. The following stacking approaches are documented in the research literature and community:

Stack	Rationale	Evidence Level	Risk Level
Semax + Selank	The most established nootropic peptide stack. Semax provides focus and cognitive acceleration; Selank provides calm and anxiety smoothing. Together they produce "calm focus" — heightened cognition without the jitteriness or anxiety that pure stimulants can cause.	Moderate (clinical use in Russia)	Low
Semax + Dihexa	Combines acute cognitive enhancement (Semax's BDNF/dopamine effects) with structural neural repair (Dihexa's synaptogenesis). Theoretical synergy for post-injury or age-related cognitive decline models.	Low (preclinical only)	Moderate
Selank + Dihexa	Addresses anxiety alongside structural cognitive repair. Useful in models where stress or anxiety may impair neuroplasticity and recovery.	Low (community/anecdotal)	Moderate
Semax + Selank + Dihexa	The full cognitive stack: focus (Semax) + calm (Selank) + neuroplasticity (Dihexa). Each compound should be evaluated individually before combining. Start with the lowest dose of each.	Low (community/anecdotal)	Moderate–Higher

9. Safety Profiles & Risk Assessment

Safety Parameter	Semax	Selank	Dihexa
Common Side Effects	Nasal irritation, headache, sleep disruption (if dosed late)	Nasal irritation, nasal dryness	Unknown (no human data); theoretical growth-factor concerns
Dependence Risk	None documented	None documented (non-sedating, no withdrawal)	Unknown
Overdose Risk	Low (wide therapeutic window in clinical use)	Low (comparable to Semax)	Unknown (no human data)
Cancer Concern	None raised	None raised	Theoretical (HGF/c-Met is a growth factor pathway active in many tissues; chronic activation may carry risk)
Contraindications	Pregnancy, severe psychiatric conditions	Pregnancy; concurrent CNS-active agents (consult specialist)	Cancer history, first-degree family cancer history, pregnancy
WADA Status	Likely prohibited (S0 blanket ban)	Likely prohibited (S0 blanket ban)	Likely prohibited (S0 blanket ban)
Years in Clinical Use	40+ years (Russia)	17+ years (Russia, approved 2009)	0 years (no human approval)

10. Evidence Quality & Human Data

Understanding the evidence tier for each compound is critical for research design and ethical review:

Compound	Evidence Tier	Human Data	Western Literature
Semax	Clinical (Russian)	Approved for stroke, cognitive disorders, optic nerve disease. Clinical trials in 110+ post-stroke patients. Added to Russia's Vital & Essential Drugs List (2011).	Mechanistic confirmation in PubMed (BDNF/TrkB, dopaminergic activation). No Western-regulator-grade RCT.
Selank	Clinical (Russian)	Approved for generalized anxiety disorder (2009). Open-label studies with active benzodiazepine comparator showed less sedation and no withdrawal.	GABAergic gene-expression effects confirmed in Frontiers in Pharmacology (2017). Antiviral activity documented.
Dihexa	Preclinical only	Zero published human clinical trials. All evidence from rodent models (Washington State University).	Peer-reviewed preclinical publications exist. No regulatory submission to FDA or EMA.

Bottom line on evidence: The Western literature confirms the mechanisms described by Russian groups for Semax and Selank (BDNF upregulation, dopaminergic activation, GABA-A subunit mRNA modulation, immune modulation). What it does not provide is independent Western confirmation of clinical efficacy. For Dihexa, the preclinical data is genuinely impressive but entirely animal-based — anyone citing "clinical evidence" for Dihexa in humans is reaching.

11. Sourcing & Quality Standards for Research

When procuring Semax, Selank, or Dihexa for research purposes, the following quality parameters are essential:

Quality Verification Checklist

• ✅ HPLC purity ≥98% — verified by reverse-phase HPLC with UV detection
• ✅ Mass spectrometry identity confirmation — molecular weight verification by LC-MS or MALDI-TOF
• ✅ Batch-specific Certificate of Analysis (COA) — including purity, identity, residual solvent, and peptide content
• ✅ Endotoxin screening — LAL-tested, LPS-free for in vivo research applications
• ✅ Sequence confirmation — amino acid analysis or sequencing to verify correct peptide sequence
• ✅ Sterile packaging — lyophilized in nitrogen-sealed amber vials with rubber stoppers
• ✅ Cold chain documentation — storage and shipping temperature logs

Red Flags to Watch For

Storage Guidelines

Compound	Lyophilized Storage	Reconstituted Storage	Shelf Life
Semax	−20°C, sealed, protected from light	2–8°C (refrigerated); use within 14 days	24 months lyophilized at −20°C
Selank	−20°C, sealed, protected from light	2–8°C (refrigerated); use within 14 days	24 months lyophilized at −20°C
Dihexa	−20°C, sealed, protected from light	−80°C aliquoted; avoid freeze-thaw cycles	24 months lyophilized at −20°C

12. Frequently Asked Questions

13. Conclusion & Key Takeaways

Semax, Selank, and Dihexa represent three distinct approaches to cognitive peptide research — each targeting a fundamentally different brain pathway. Semax amplifies BDNF and dopamine for acute focus and neuroprotection. Selank modulates GABA and enkephalins for calm clarity and anxiety reduction. Dihexa drives HGF/c-Met-mediated synaptogenesis for structural neural repair. They are not interchangeable, and the right choice depends entirely on the research question being asked.

For researchers new to cognitive peptides, Semax and Selank offer the best combination of mechanistic interest and safety characterization — backed by decades of Russian clinical use and confirmed mechanistic data in Western literature. Dihexa represents the frontier: extraordinary preclinical potency, oral bioavailability, and a mechanism that goes beyond modulation into structural neural construction — but with corresponding uncertainty about long-term human safety.

Key Takeaways

• Different mechanisms: Semax = BDNF/dopamine; Selank = GABA/enkephalins; Dihexa = HGF/c-Met synaptogenesis
• Different onset profiles: Semax and Selank work in minutes; Dihexa's effects build over days to weeks
• Different evidence tiers: Semax and Selank have human clinical data (Russia); Dihexa is preclinical only
• Different risk profiles: Semax and Selank are low-risk with decades of use; Dihexa carries theoretical growth-factor concerns
• Complementary, not interchangeable: They can be stacked for synergistic research protocols
• Storage matters: All three require cold storage; Semax is particularly degradation-sensitive at room temperature
• Sourcing quality is critical: Always require HPLC ≥98%, MS confirmation, batch-specific COAs, and endotoxin screening
• Research use only: None are FDA-approved; all procurement should be for legitimate research purposes